Let’s use Keytruda (pembrolizumab) as an example… it is an FDA-approved immunotherapy drug used to treat several cancers, including melanoma, lung, bladder, head and neck, breast, and colorectal cancers. Average cost: around $11,000–$13,000 per dose (given every 3–6 weeks) It’s a PD-1 checkpoint inhibitor that blocks the PD-1 receptor on immune cells, releasing the immune “brakes” so T-cells can attack cancer cells that hide from detection. 🤷🏼‍♀️Common side effects: fatigue, nausea, rash, join

Patients with stage III or IV melanoma can benefit from adjuvant pembrolizumab. Whether outcomes with neoadjuvant plus adjuvant pembrolizumab would be better than those with adjuvant therapy alone is unknown. New research findings are summarized in a short video. https://nej.md/3YaD6qN | The New England Journal of Medicine